(Written By Feng X.B Translated By YU.Y.C）From October 28 to 30, the 75th iENA was held at the local International Exhibition Center in Nuremberg, Germany. As one of the key innovation projects of the country of honor, the "remote digital & Intelligent clinical trial technical platform" developed by Academician Dong Jiahong of Beijing Tsinghua Changgung Hospital affiliated to Tsinghua University was exhibited and won the gold award.

The platform will innovate and apply the most cutting-edge artificial intelligence and trusted computing technology in medical clinical trials, and then realize the remote intelligent recruitment of clinical subjects, intelligent transcription of medical record data, and in-depth information mining of scientific research data.

The platform is based on a large model in the medical field with excessive parameters, which can effectively transform the original clinical source data into actionable intelligent identification, and its multi-center distributed storage and blockchain bookkeeping technology can enhance data security and privacy. Machine Trust breaks through the traditional data island problem by utilizing remote intelligent technology and virtualization platform. It has launched patient-centered remote/hybrid clinical research and drug device trials, opening up the "highway" of digital intelligent clinical research in the entire industry.

It is reported that since 2021, under the guidance of the Beijing Municipal Health Commission and Beijing Municipal Medical Products Administration, Tsinghua University as the technical design unit, Beijing Tsinghua Changgung Hospital as the pilot center, and The China Information Technology Security Evaluation Center as the security agency, the pilot project of "remote digital & Intelligent clinical trial technical platform" has been carried out in Beijing. Promote clinical trials and research pilot work based on digital intelligence technology, such as remote visits, automatic desensitization of case data transcription, and remote monitoring. At present, more than 10 clinical studies on innovative drugs, including the Down-Staging of liver cancer in Beijing Tsinghua Changgung Hospital and the treatment of esophageal cancer by PD-1, have been supported and completed.

The platform project has been extended to Huaxin Hospital affiliated to Tsinghua University, Yuquan Hospital affiliated to Tsinghua University and a number of Third-class hospital research-oriented hospitals, and has cooperated with more than 10 head medicine research and development units. In the future, Beijing Tsinghua Changgung Hospital will continue to expand cooperation to 10 Third-class hospitals in 6 districts of the city, as well as more than 50 cooperative hospitals and head innovative pharmaceutical enterprises in the country, helping to form a new trend of national clinical research digital economy, and creating a new chapter for pharmaceutical clinical research.